Emergent BioSolutions | EBS - Przychody Ze Sprzedaży





Obroty Zmiana Data
Acadia Pharmaceuticals USD 268.06M 15.94M 2026-03
Akebia Therapeutics USD 57.62M 1.14M 2025-12
ALKERMES USD 392.91M 8.41M 2026-03
Alnylam Pharmaceuticals USD 1.17B 70M 2026-03
Amarin USD 49.22M 451K 2025-12
ANI Pharmaceuticals USD 237.5M 9.56M 2026-03
BioMarin Pharmaceutical USD 766M 109M 2026-03
Coherus Biosciences USD 12.75M 1.18M 2025-12
Emergent BioSolutions USD 276.6M 6.1M 2023-12
Exelixis USD 610.8M 12.14M 2026-03
Glaxosmithkline GBP 10.09B 1.37B 2026-03
Heron Therapeutics USD 40.59M 2.38M 2025-12
Ionis Pharmaceuticals USD 246M 43M 2026-03
Ironwood Pharmaceuticals USD 106.51M 58.8M 2026-03
Lexicon Pharmaceuticals USD 5.49M 8.69M 2025-12
Lonza CHF 3.58B 63M 2025-06
Merck USD 16.29B 110M 2026-03
Moderna USD 389M 289M 2026-03
Myriad Genetics USD 200.4M 9.4M 2026-03
Nektar Therapeutics USD 21.81M 2.32M 2025-12
Neurocrine Biosciences USD 811M 5.5M 2026-03
Pacira USD 177M 19.87M 2026-03
Pfizer USD 14.5B 3.08B 2026-03
PTC Therapeutics USD 273M 108.3M 2026-03
Sanofi EUR 11.24B 60M 2026-03
Sarepta Therapeutics USD 730.8M 287.9M 2026-03
United Therapeutics USD 781.5M 8.7M 2026-03
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Xoma USD 25K 5M 2024-09